CJC-1295 / Ipamorelin
What it is
CJC-1295 is a growth hormone-releasing hormone analogue and ipamorelin is a growth hormone secretagogue. They are sometimes prescribed in combination. Neither is FDA-approved and neither has an approved indication.
How it is used
Administered by subcutaneous injection on a protocol set by the prescriber. As with other peptides in this category, protocols are not standardised.
What a provider evaluates first
- Baseline IGF-1 and relevant endocrine markers
- History of malignancy
- Whether an approved therapy is appropriate for the same goal
Considerations and monitoring
- Not FDA-approved; no approved indication
- CJC-1295 was removed from 503A Category 2 in April 2026 but not moved to Category 1
- Evidence in humans is limited and protocols vary widely
Questions about cjc-1295 / ipamorelin
Are peptides FDA-approved?
The peptides discussed in this category are not FDA-approved and have no approved indication. They are compounded preparations prescribed at the discretion of a licensed provider. There is no USP monograph for them, human clinical evidence is limited, and dosing protocols are not standardised between prescribers. Anyone presenting them as proven therapies is overstating what is known.
What is the current regulatory status of BPC-157?
In late 2023 the FDA placed BPC-157 into 503A Category 2, which effectively prohibited compounding it. In April 2026 it was removed from Category 2, but it was not added to the 503A positive list — the list of substances affirmatively permitted — so it became neither prohibited nor authorised. In July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 to recommend adding it to that list. That vote is a recommendation rather than a rule: the FDA has not acted on it, and doing so requires formal rulemaking that ordinarily takes a year or more. As things stand it remains without FDA approval and without an approved indication.
Part of Peptide Therapy.